Evidence map›Paper›PMID 31165047›Full record

ArticleFrontiers in oncology2019

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.

Ramy Gadalla, Babak Noamani, Bethany L MacLeod, Russell J Dickson, Mengdi Guo, Wenxi Xu, Sabelo Lukhele, Heidi J Elsaesser, Albiruni R Abdul Razak, Naoto Hirano and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Immunological biomarkers of aging.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Ramy GadallaTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Babak NoamaniTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Bethany L MacLeodTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Russell J DicksonTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Mengdi GuoDepartment of Immunology, University of Toronto, Toronto, ON, Canada.
Wenxi XuTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Sabelo LukheleTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Heidi J ElsaesserTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Albiruni R Abdul RazakTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Naoto HiranoTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Tracy L McGahaTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Ben WangTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Marcus ButlerTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Cynthia J GuidosDepartment of Immunology, University of Toronto, Toronto, ON, Canada.
Pam S OhashiTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Lillian L SiuTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
David G BrooksTumor Immunology Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
Princess Margaret Cancer Centre · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

Princess Margaret Phase I Consorium (PMP1C)UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney · 2014 to 2026
$16.6M
NCI NIH HHS UM1 CA186644
6 · The paper itself

Abstract

Flow cytometry is a widely applied approach for exploratory immune profiling and biomarker discovery in cancer and other diseases. However, flow cytometry is limited by the number of parameters that can be simultaneously analyzed, severely restricting its utility. Recently, the advent of mass cytometry (CyTOF) has enabled high dimensional and unbiased examination of the immune system, allowing simultaneous interrogation of a large number of parameters. This is important for deep interrogation of immune responses and particularly when sample sizes are limited (such as in tumors). Our goal was to compare the accuracy and reproducibility of CyTOF against flow cytometry as a reliable analytic tool for human PBMC and tumor tissues for cancer clinical trials. We developed a 40+ parameter CyTOF panel and demonstrate that compared to flow cytometry, CyTOF yields analogous quantification of cell lineages in conjunction with markers of cell differentiation, function, activation, and exhaustion for use with fresh and viably frozen PBMC or tumor tissues. Further, we provide a protocol that enables reliable quantification by CyTOF down to low numbers of input human cells, an approach that is particularly important when cell numbers are limiting. Thus, we validate CyTOF as an accurate approach to perform high dimensional analysis in human tumor tissue and to utilize low cell numbers for subsequent immunologic studies and cancer clinical trials.

Indexed as

cancer clinical trialsCyTOFflow cytometryimmune studiesimmunotherapy

Identifiers

PMID31165047
PMCPMC6534060
OpenAlexW2945493637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.